Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback